Allergy Therapeutics Share Discussion Threads

[kevraff] 19/1/2022 20:51

Strange decline today, inclined to say this is due to wider market conditions of late than anything else.

[jpuff] 19/1/2022 17:43

Depressing

[jimmyloser] 19/1/2022 16:11

ok - Take heart, you do not have a highly credible CEO and brokers issue such a strong forward looking statement
Read it.

[richsawko] 19/1/2022 15:51

No knowledge of anything but just strange that there is such a string pull back after relative stability for a good period. I was wondering whether some news may have been leaked to cause this

[jimmyloser] 19/1/2022 15:06

Please elaborate on your post Rich. If you can.

[richsawko] 19/1/2022 14:48

This looks as though there must be bad news coming!

[richsawko] 19/1/2022 12:47

We can only hope

[jimmyloser] 19/1/2022 12:34

Yes I would agree, we do appear to be taking a bit of a kicking so to speak. I may be in cloud cuckoo land but have read and re-read the latet RNS,I cannot find anything remotely alarming in there. I understand cutting old lines to focus on SCIT. I am encouraged by the cash position and the pipeline and the stages that they are at and I look forward to the future with optimism.

Am I alone?

[richsawko] 19/1/2022 12:24

Very disappointing this drop. Are we resigned to always retracing lows

[wizzkid211] 13/1/2022 08:00

Allergy Therapeutics PLC Half Year Trading Update & Notice of Results
13/01/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Thursday 13 January 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 2762Y

Allergy Therapeutics PLC

13 January 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Half Year Trading Update 2022 and Notice of Results

- VLP Peanut IND application submitted to FDA with a protocol enabling Phase I trial (named PROTECT); expected results in H1 2023 ahead of original Q4 2023 data readout

- IMP VLP Peanut batch manufactured and ready for start of upcoming PROTECT trial
- Strategic streamlining of products to focus on SCIT and innovative allergy treatments
- Strong cash position to support Grass MATA MPL pivotal Phase III field studies and Phase I VLP Peanut PROTECT trial

- Phase III Grass MATA MPL trial on track to start Q3 2022 following impressive results from exploratory field trial

13 January 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the six months ended 31 December 2021 ahead of its Half Year Results to be announced on 3 March 2022.

Financials

Reported revenues for the six months ended 31 December 2021 are expected to be GBP48.7m (2020: GBP54.0m), representing a 10% reduction on a reported basis (down 5% on constant currency basis). This is primarily due to the previously disclosed strategic streamlining of non-differentiated older products to maintain focus on short course subcutaneous immunotherapy (SCIT) and innovative allergy treatments. On this revised basis revenues have increased 3% on a like for like product and phasing basis (on constant currency basis).

Revenues were also affected by phasing, headwinds in Germany and the continuing effect of COVID-19 in Italy and Germany. However Spain, the Group's second most important market, saw a double-digit growth in sales, while the Netherlands, UK and Rest of World (RoW) also grew strongly. There was double-digit growth for key products Pollinex, Venomil and Acarovac (on constant currency basis).

Reported revenue for the year is likely to be down on the 2021 financial year by an upper single digit percentage, but through planned cost reductions in the second half of the year, the Board remains confident that market consensus for the operating profit pre R&D this financial year will be achieved.

The Group has continued to generate good cash conversion, with a strong cash balance at the end of December 2021 of GBP41.4m (31 December 2020: GBP48.3m).

On current internal assumptions and as previously communicated, the Group will be able to fund the Grass MATA MPL Phase III trial (G306), as well as the VLP Peanut Phase I PROTECT trial, from existing resources with a small amount of additional debt.

Regulatory

The Group has successfully submitted the Investigational New Drug (IND) application for VLP Peanut to the US Food and Drug Administration (FDA). Following consultation with experts in the field, the IND application includes a protocol for the upcoming Phase I PROTECT trial, moving the planned paediatric and adolescent arms into a future Phase II trial. As a result, topline data from the Phase I PROTECT trial, in adult patients, would be anticipated in H1 2023, ahead of the original intended Q4 2023 data readout.

Furthermore, the batch of investigational medicinal product (IMP) intended for use in the upcoming Phase I PROTECT trial has been successfully manufactured, tested and released. This product aims to revolutionise the peanut allergy market as a treatment that has the potential to provoke a disease-modifying effect and to bring a significant positive impact to the lives of patients and families affected by peanut allergy, and to health systems. The market for peanut allergies is expected to be around $8bn worldwide.

Following the outcome of the Grass MATA MPL exploratory field trial in October 2021 which showed efficacy of 36.8% in an extended posology, the Group is now on track to begin the Grass MATA MPL pivotal Phase III trial (G306) in the autumn of this calendar year.

Manuel Llobet, CEO at Allergy Therapeutics , stated: "2022 is going to be a pivotal year for Allergy Therapeutics with the VLP Peanut Phase I PROTECT trial and MATA MPL Phase III trial (G306) commencing during the calender year. We continue to be very encouraged by the data and the clinical progress supporting these highly innovative product trials. The Group has continued to perform and I am encouraged by our response to the challenges from what continues to be a tough environment. Our focus on providing innovative allergy treatments to patients in need, as well as delivering a strong, differentiated R&D pipeline remains key to our strategy. We are confident in the Group's commercial capabilities despite being cautious due to COVID-related uncertainties and we look forward to reporting the significant progress expected in our clinical pipeline."

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

[jimmyloser] 04/1/2022 15:44

rich
fwiw, this is not surprising as we are drifting on the wind on very low action, until we get further news feed impo

I personally remain relaxed.

[richsawko] 04/1/2022 12:52

Here we go again, retracing back into the 20's. I must be too optimistic about this share as I always think it is about to explode when it rises only to see it drop again!

[jimmyloser] 23/12/2021 07:46

This is an oral treatment that has been around for a while. The parent is Aimmune and they in turn were bought by Nestle for mega bucks which hopefully when the time is right is the way that we will go.

As I understand it, this is a long course of tablets and our unique approach is a SCIT.

No doubt like many others on here, I am puzzled as to why we have had no update on that imminent meeting that they have advised us of TWO MONTHS AGO, with the FDA.

Relax - I am.

dyor

In January 2020, less than 10 years after its founding, Aimmune became the first company to have an FDA-approved treatment for peanut allergy. A respected partner of choice with world-leading companies, Aimmune’s development pipeline also includes investigational candidates for other prevalent food allergies, including multi-tree nut. In October 2020, Aimmune Therapeutics was acquired by Nestlé Health Science, a recognized leader in the field of nutritional science.

[jpuff] 23/12/2021 06:07

Is this ours or a competitor whose pipped us to the post?

[jpuff] 23/12/2021 06:06

Life-changing peanut allergy treatment to be given to children in UKSent from my iPhone

[wizzkid211] 23/11/2021 14:15

RNS Number : 3040T

Allergy Therapeutics PLC

23 November 2021

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

23 November 2021 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2021 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.

Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.

The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.

[jimmyloser] 18/11/2021 17:47

DukeI and several others have been with AGY for many years. When I read your post earlier today I didn't respond but I knew from my own experience that the company would willingly answer your question as best as they are able. Your response confirms my own views.The lack of action in the shares is for me an encouraging sign of investor confidenceGood LuckJl

[petewy] 18/11/2021 17:38

Thanks duke. I quit if a company doesn't answer an enquiry (email).

[2theduke] 18/11/2021 17:28

I’ve now had a very detailed and helpful response from the company.
This was confidence building and I like the open and prompt response - not always the case.
In short: both avenues effective, one needs patient adherence, us is mainly non oral.
Imo dyo etc

[2theduke] 18/11/2021 10:50

Could I ask for a view on the challenges & advantages of subcutaneous vs oral products for allergies.
I note a new oral product was mentioned as a competitor now in the Netherlands, albeit sales remained resilient.
Looking at research papers they note limited research between the two methods albeit that there does not appear to be a difference in effectiveness.
Whilst AGY seem well positioned in the EU and US (in due course) for subcutaneous, I really want to know more about the oral competition before increasing investments.
I've emailed the company as well if they can share insight.

[km18] 12/11/2021 13:59

AGY is a visionary immunology business focused on R&D of allergy treatments and operating in Europe and looking forward to US market opportunity. The company specializes in diagnosis and treatment of allergy. What differentiates them is that average treatment in the market is of around 12-15 course injections, whereas theirs consists of 6. They have growing market share in EU and aim to enter the largest allergy market – the US, further supported by 8 new products in their pipeline.
AGY has generated a 25% pre-R&D increase in operating profit in 2020. Operating performance in 2016 was affected by big expenditures on R&D. 2020 gross performance has supported successfully the R&D investments in the group. The company has seen significant increase in cash with low movements in accruals. Cash is expected to further increase, and operating profit is expected to be 8% above expectations.
Latest report consisting the preliminary annual results are definitely in favour of the stock. Revenue grew by 8% reaching the Stockopedia forecasted figure of £84.3m. Net profit is above the forecast at £2.9m and gross profit is ahead of 2020 figures. We should note that profit for the year is significantly below the last year’s level due to high R&D cost (more than double the 2020). Outlook is positive and they have new trials coming...keep up to date with stocks with WealthOracleAM

[jimmyloser] 28/10/2021 15:33

Something bewing here, large buys to fall or share tip?
Maybe the traders are finished and it is back to us investors

mmmm

[jimmyloser] 27/10/2021 07:07

G306 brekthrough and firmly on track, Peanuts trials very successful, Cheryl McD appointed, mention of Nasdaq listing and Chinese investors buying still. FDA meetings imminent
Read the runes

Impo
Dyor

[catch007] 26/10/2021 11:56

Yesterday's froth wiped out now on share price an opportunity to top up may well present itself now imho